13-week randomized double-blind trial of lumiracoxib versus celecoxib and placebo in primary hip osteoarthritis

Phase 3, randomised, double-blind trial of lumiracoxib in primary coxarthrosis (3 arms), sponsored by Novartis. Primary endpoints: WOMAC pain sub-scale score at 13 weeks, WOMAC difficulty performing daily activities (DPDA) sub-scale at 13 weeks and 1 more. Started Oct 2005; status: completed.